An evaluation of data from the Global Burden of Disease found that nonalcoholic fatty liver disease (NAFLD) is a main driver of chronic liver disease and has increased among adolescents and young adults.
Over the last decade, nonalcoholic fatty liver disease (NAFLD) has become the main driver of chronic liver disease (CLD) incidence, although viral hepatitis remains the most common cause of CLD deaths, according to a study published in Hepatology.
Deaths from cirrhosis have increased significantly from 1.9% of total global deaths in 1990 to 2.4%, the authors noted, and nonalcoholic steatohepatitis (NASH) is the main culprit since the age-specific death rates for all other causes of liver disease have decreased.
They added that “obesity and type 2 diabetes mellitus have been considered the most important drivers of changes in the profile of liver disease in the United States and across the globe. This growing burden has led to recent data suggesting that NAFLD will become the most common indication for liver transplantation in the near future.”
The researchers described the global burden of CLD among individuals between the ages of 15 and 29 years using data from the Global Burden of Disease (GBD). The GBD is coordinated by the Institute for Health Metrics and Evaluation. The Cause of Death database was utilized to model deaths due to CLD.
In 2019, there were 290 million CLD prevalent cases, 17.2% of which were among individuals aged 15 to 29 years; 232,072 CLD incident cases, 11.2% of which were in the 15-29–year age group; and 55,515 CLD deaths, 3.8% of which were in the 15-29–year age group.
The Middle East and North Africa region had the highest prevalence of CLD with 79% of those aged 15 to 19 years, 85% of those aged 20 to 24 years, and 87% of those aged 25 to 29 years having CLD. The prevalence was largely driven by NAFLD, according to the authors. The next highest prevalence of CLD was in the regions of Western Sub-Saharan Africa, East Asia, Central Sub-Saharan Africa, Southern Sub-Saharan Africa, Central Asia, and Southeast Asia. The regions with the lowest prevalence of CLD were Southern Latin America, high-income North America, high-income Asia Pacific, and Western Europe.
Central Asia, South Asia, and Central Sub-Saharan Africa had the highest death rates from CLD compared with Australasia, high-income Asia Pacific, Western Europe, and high-income North America, which had the lowest CLD death rate (≥4.5 per 100,000 vs <0.51 per 100,000).
The researchers identified the following trends:
The researchers noted that NAFLD/NASH is an increasingly important cause of CLD and the finding that the proportion of CLD deaths with NAFLD worsened in almost every region of the world was “alarming.”
“Global policies to address NAFLD and its associated risk factors of obesity and type 2 diabetes with targeted interventions for both adults and the young population (ages 15-29) must be developed as this younger age group are the drivers of future socioeconomic prosperity across the world,” they concluded.
Reference
Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of non-alcoholic fatty liver disease (NAFLD) and chronic liver disease (CLD) among adolescents and young adults. Hepatology. Published online November 6, 2021. doi:10.1002/hep.32228
Healing Wounds Through Peer Support
September 16th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this third episode, we speak with Kim MacDonald-Wilson, ScD, CPRP, and Tracy Carney, CPS, CPRP.
Listen
Vaccine Hesitancy: COVID-19 to Influenza
October 22nd 2024Vaccine hesitancy grew more prominently in the wake of COVID-19 and the spread of misinformation. This flu season, seeking out reliable sources of health information will help individuals make the best decisions to protect themselves.
Read More
Combatting the Opioid Epidemic: Insights From the Front Lines
September 2nd 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this first episode, we speak with Michael Lynch, MD, associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.
Listen
Methadone Associated With Lower Risk of Treatment Discontinuation in Opioid Use Disorder
October 17th 2024Amidst ambiguous international guidelines for first-line treatment of opioid use disorder, a new population-based study sheds light on the benefits of methadone vs buprenorphine/naloxone for holding off treatment discontinuation.
Read More
Healing Wounds Through Peer Support
September 16th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this third episode, we speak with Kim MacDonald-Wilson, ScD, CPRP, and Tracy Carney, CPS, CPRP.
Listen
Vaccine Hesitancy: COVID-19 to Influenza
October 22nd 2024Vaccine hesitancy grew more prominently in the wake of COVID-19 and the spread of misinformation. This flu season, seeking out reliable sources of health information will help individuals make the best decisions to protect themselves.
Read More
Combatting the Opioid Epidemic: Insights From the Front Lines
September 2nd 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this first episode, we speak with Michael Lynch, MD, associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.
Listen
Methadone Associated With Lower Risk of Treatment Discontinuation in Opioid Use Disorder
October 17th 2024Amidst ambiguous international guidelines for first-line treatment of opioid use disorder, a new population-based study sheds light on the benefits of methadone vs buprenorphine/naloxone for holding off treatment discontinuation.
Read More
2 Commerce Drive
Cranbury, NJ 08512